** Analysts expect Indian drugmaker Dr Reddy's Laboratories REDY.NS to report near 14% rise in Q4 consol net PAT, rev to grow 18%, per data compiled by LSEG
** REDY's reported 2.3% rise in Q3 profit, and 36.5% in Q4 a year ago
** Jan-March qtr results to be helped by new drug launches in oncology and other chronic therapy areas, analysts say
** India business to see 15% YoY growth on incremental sales from acquired vaccine business from Sanofi India SANO.NS, says brokerage HDFC Securities
** Stock trading flat on the day vs 1.2% fall in the benchmark Nifty 50 index .NSEI
** REDY shares fell 17.6% in the Jan-March quarter, snapping eight straight quarterly gains, on Trump tariff woes
** REDY down ~2.6% this week, snapping three weeks of gains
** REDY among 8 stocks on 20-member pharma index rated "hold", rest, including rival Cipla CIPL.NS rated "buy" or higher- data compiled by LSEG
** REDY's down ~17% YTD while Nifty Pharma index .NIPHARM is down ~10.2%
($1 = 85.5200 Indian rupees)
(Reporting by Anuran Sadhu in Bengaluru)
((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.